TransMedics Announces Inducement Grants under NASDAQ Listing Rule

TransMedics Group, Inc. recently announced the granting of non-qualified stock options and restricted stock units to five employees as an inducement for their entry into employment with the company. The stock options allow for the purchase of 3,815 shares of TransMedics’ common stock, while 2,479 restricted stock units were also granted.

The stock options were granted with an exercise price of $83.14 per share, based on the closing price of the common stock on the Nasdaq Global Market on February 23, 2024. Vesting of the shares will occur in installments over a four-year period, contingent upon the employees’ continued service with the company. The options have a 10-year term and are part of the TransMedics Group, Inc. Inducement Plan.

TransMedics is a medical technology company based in Andover, Massachusetts, specializing in organ transplant therapy for patients with end-stage lung, heart, and liver failure. The company focuses on portable extracorporeal warm perfusion and assessment of donor organs for transplantation, with a mission to increase the availability and quality of organs for those in need.